Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BAL PHARMA vs MERCURY LAB. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BAL PHARMA MERCURY LAB. BAL PHARMA/
MERCURY LAB.
 
P/E (TTM) x 40.8 24.3 168.1% View Chart
P/BV x 2.3 2.2 103.3% View Chart
Dividend Yield % 1.1 0.4 260.5%  

Financials

 BAL PHARMA   MERCURY LAB.
EQUITY SHARE DATA
    BAL PHARMA
Mar-23
MERCURY LAB.
Mar-23
BAL PHARMA/
MERCURY LAB.
5-Yr Chart
Click to enlarge
High Rs1341,000 13.4%   
Low Rs63390 16.3%   
Sales per share (Unadj.) Rs193.9627.8 30.9%  
Earnings per share (Unadj.) Rs1.746.5 3.6%  
Cash flow per share (Unadj.) Rs7.567.2 11.1%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Avg Dividend yield %1.00.5 201.1%  
Book value per share (Unadj.) Rs40.7380.2 10.7%  
Shares outstanding (eoy) m15.691.20 1,307.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.51.1 46.0%   
Avg P/E ratio x59.214.9 395.7%  
P/CF ratio (eoy) x13.210.3 127.5%  
Price / Book Value ratio x2.41.8 132.9%  
Dividend payout %59.97.5 795.8%   
Avg Mkt Cap Rs m1,549834 185.8%   
No. of employees `000NANA-   
Total wages/salary Rs m553139 397.6%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m3,042753 403.8%  
Other income Rs m917 54.7%   
Total revenues Rs m3,052771 396.0%   
Gross profit Rs m25386 293.0%  
Depreciation Rs m9125 367.6%   
Interest Rs m1234 3,401.7%   
Profit before tax Rs m4775 63.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2119 111.2%   
Profit after tax Rs m2656 46.9%  
Gross profit margin %8.311.4 72.5%  
Effective tax rate %44.825.5 175.5%   
Net profit margin %0.97.4 11.6%  
BALANCE SHEET DATA
Current assets Rs m2,282417 547.0%   
Current liabilities Rs m2,093164 1,274.3%   
Net working cap to sales %6.233.6 18.4%  
Current ratio x1.12.5 42.9%  
Inventory Days Days87 107.3%  
Debtors Days Days1,1281,035 108.9%  
Net fixed assets Rs m829259 320.3%   
Share capital Rs m15712 1,307.5%   
"Free" reserves Rs m481444 108.3%   
Net worth Rs m638456 139.8%   
Long term debt Rs m30524 1,260.8%   
Total assets Rs m3,110676 460.2%  
Interest coverage x1.421.7 6.4%   
Debt to equity ratio x0.50.1 901.8%  
Sales to assets ratio x1.01.1 87.7%   
Return on assets %4.88.8 54.6%  
Return on equity %4.112.2 33.6%  
Return on capital %18.116.3 110.7%  
Exports to sales %66.425.3 262.3%   
Imports to sales %22.40.4 6,378.1%   
Exports (fob) Rs m2,020191 1,059.0%   
Imports (cif) Rs m6833 25,756.2%   
Fx inflow Rs m2,020191 1,059.0%   
Fx outflow Rs m7168 9,060.3%   
Net fx Rs m1,305183 713.4%   
CASH FLOW
From Operations Rs m-1825 -75.2%  
From Investments Rs m-222-11 2,098.6%  
From Financial Activity Rs m244-10 -2,408.7%  
Net Cashflow Rs m44 97.7%  

Share Holding

Indian Promoters % 47.1 73.7 63.9%  
Foreign collaborators % 4.2 0.0 -  
Indian inst/Mut Fund % 0.1 0.0 -  
FIIs % 0.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 48.8 26.3 185.2%  
Shareholders   15,060 1,161 1,297.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BAL PHARMA With:   SUN PHARMA    CIPLA    DIVIS LABORATORIES    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on BAL PHARMA vs MERCURY LAB.

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

BAL PHARMA vs MERCURY LAB. Share Price Performance

Period BAL PHARMA MERCURY LAB. S&P BSE HEALTHCARE
1-Day -4.40% -4.12% 1.18%
1-Month -17.76% -3.92% -0.75%
1-Year 40.93% 56.06% 61.82%
3-Year CAGR 19.04% 9.86% 18.16%
5-Year CAGR 5.43% 20.84% 19.79%

* Compound Annual Growth Rate

Here are more details on the BAL PHARMA share price and the MERCURY LAB. share price.

Moving on to shareholding structures...

The promoters of BAL PHARMA hold a 51.2% stake in the company. In case of MERCURY LAB. the stake stands at 73.7%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BAL PHARMA and the shareholding pattern of MERCURY LAB..

Finally, a word on dividends...

In the most recent financial year, BAL PHARMA paid a dividend of Rs 1.0 per share. This amounted to a Dividend Payout ratio of 59.9%.

MERCURY LAB. paid Rs 3.5, and its dividend payout ratio stood at 7.5%.

You may visit here to review the dividend history of BAL PHARMA, and the dividend history of MERCURY LAB..

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.